Cure8 research brief
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Clinicians and researchers studying IBD biomarkers; adult IBD patients interested in noninvasive monitoring; labs and trialists exploring new diagnostic markers.
The authors measured serum galectin‑3, fecal calprotectin, CRP and routine labs in 40 patients with active IBD and 40 matched healthy controls. They found higher galectin‑3 in active UC versus remission and report a proposed cutpoint (≈5.199 µg/ml) with very high sensitivity and specificity in this sample.
Combining galectin‑3 with CRP and fecal calprotectin improved diagnostic performance further according to the abstract.
The findings are preliminary and from a single, small study; the abstract-level report does not provide full methodological detail here (for example, how active disease was defined, whether Crohn's results matched UC, or independent validation). Larger, independent studies would be needed before galectin‑3 could be recommended for routine clinical use.
This is an abstract-level report of a small comparative study (40 active IBD patients, 40 controls). Key details and external validation are needed before changing practice. The source is an academic journal abstract available via Europe PMC.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
